LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Genome of the Lone Star Virus Quickly Unmasked by Ultradeep Gene Sequencing

By LabMedica International staff writers
Posted on 13 May 2013
Image: Senior author Dr. Charles Chiu (Photo courtesy of Susan Merrell, University of California, San Francisco).
Image: Senior author Dr. Charles Chiu (Photo courtesy of Susan Merrell, University of California, San Francisco).
Virologist have used next generation "ultradeep" gene sequencing and analysis coupled with de novo synthesis of the viral genome to assign a unique example of the Lone Star virus (LSV) to the bunyavirus family of tick-borne viruses, which includes several human pathogens.

Depth in DNA sequencing refers to the number of times a nucleotide is read during the sequencing process. Deep sequencing indicates that the coverage, or depth, of the process is many times larger than the length of the sequence under study. The term "deep" has been used for a wide range of depths (at least 7 times), and the newer term "ultradeep" has appeared in the scientific literature to refer to even higher coverage (at least 100 times). Even though the sequencing accuracy for each individual nucleotide is very high, the very large number of nucleotides in the genome means that if an individual genome is only sequenced once, there will be a significant number of sequencing errors. Furthermore, rare single-nucleotide polymorphisms (SNPs) are common. Hence to distinguish between sequencing errors and true SNPs, it is necessary to increase the sequencing accuracy even further by sequencing individual genomes a large number of times.

In a paper published in the April 29, 2013, online edition of the journal PLOS ONE investigators at the University of California, San Francisco (USA) reported results from ultradeep sequencing that covered the LSV genome more than 1,000 times. The gene sequencing technology used for this study allowed complete reconstruction of the viral genome in less than 24 hours—significantly faster than conventional sequencing techniques, which can take days to weeks.

The LSV sample had originally been isolated from the lone star tick Amblyomma americanum. The LSV isolate was able to infect both human (HeLa) and monkey (Vero) cells. Cytopathic effects were seen within 72 hours in both cell lines; vacuolization was observed in infected Vero, but not HeLa, cells.

Viral culture supernatants were examined by unbiased deep sequencing and analysis using an in-house developed rapid computational pipeline for viral discovery, which definitively identified LSV as a Phlebovirus. De novo assembly of the full genome revealed that LSV was highly divergent, sharing less than 61% overall amino acid identity with any other bunyaviruses. Despite this sequence diversity, LSV was found by phylogenetic analysis to be part of a well-supported clade that includes members of the Bhanja group viruses, which are most closely related to severe fever with thrombocytopenia syndrome virus (SFTSV) in China and heartland virus (HRTV) in the USA.

“We did not show that Lone Star virus causes disease in humans, although the laboratory and sequencing data suggest that this is a distinct possibility,” said senior author Dr. Charles Chiu, assistant professor of laboratory medicine at the University of California, San Francisco.

“Nature is continually throwing us curveballs,” said Dr. Chiu. “We will likely always be faced with the threat of novel outbreak viruses originating in animals or insects. It will be extremely important to identify and characterize those viruses as quickly as possible – to get a head start on the development of diagnostic assays for surveillance and drugs, or vaccines for treatment – before they have a chance to really spread. By the time SARS was identified and sequenced using conventional methods, more than a week of time had been lost. That kind of delay could be quite risky in a virus that spreads rapidly in human populations.”

Related Links:
University of California, San Francisco


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more